Top News

Samsung Biologics to Acquire Full Ownership of Samsung Bioepis in $2.3 Billion Deal

January 28, 2022

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

UCB Acquires Zogenix for $1.9 Billion

January 25, 2022

UCB and Zogenix have agreed to an acquisition deal totaling nearly $2 billion.

FUJIFILM Diosynth Biotechnologies to Create Major Biopharma Manufacturing Site in United Kingdom

December 16, 2021

FUJIFILM Diosynth Biotechnologies plans to invest £400 million (US$528 million) to expand its Billingham, Teeside facility in the United Kingdom.

Pfizer Acquires Arena Pharmaceuticals for $6.7 Billion

December 15, 2021

Pfizer’s $6.7 billion acquisition of Arena will give them access to a portfolio of immuno-inflammatory therapies.

Pfizer and BioNTech Provide Update on Omicron Variant

December 09, 2021

Pfizer found that two-dose recipients exhibited a more than 25-fold reduction in neutralization titers against Omicron relative to wild-type.

AstraZeneca Signs Blockbuster Deal With Ionis for TTR Amyloidosis Treatment

December 08, 2021

AstraZeneca struck a deal worth up to more than $3.5 billion with Ionis Pharmaceuticals for the rights to develop and commercialize their transthyretin (TTR) amyloidosis treatment.

Recordati Acquires EUSA Pharma for $845 Million

December 06, 2021

Recordati’s blockbuster acquisition of EUSA Pharma gives them access to a portfolio of four drugs that treat rare cancers.

EMA Recommends Pfizer and BioNTech’s COVID-19 Vaccine for Children

November 29, 2021

The Comirnaty vaccine received a positive opinion from the EMA’s CHMP for children five to under 12 years of age.

FDA Authorizes COVID-19 Boosters for All Adults

November 19, 2021

FDA has amended its EUA for Pfizer-BioNTech’s and Moderna’s COVID-19 booster to include all individuals aged 18 or older.

Novo Nordisk Acquires Dicerna for $3.3 Billion

November 19, 2021

Novo Nordisk’s 3.3 billion acquisition of Dicerna gives them access to their RNAi technology.